Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Net Income (2022 - 2025)

BioXcel Therapeutics has reported Net Income over the past 4 years, most recently at -$13.9 million for Q4 2025.

  • Quarterly results put Net Income at -$13.9 million for Q4 2025, up 3.57% from a year ago — trailing twelve months through Dec 2025 was -$65.2 million (up 18.56% YoY), and the annual figure for FY2025 was -$64.7 million, up 18.86%.
  • Net Income for Q4 2025 was -$13.9 million at BioXcel Therapeutics, up from -$18.4 million in the prior quarter.
  • Over the last five years, Net Income for BTAI hit a ceiling of -$13.5 million in Q1 2025 and a floor of -$54.1 million in Q2 2023.
  • Median Net Income over the past 4 years was -$23.9 million (2023), compared with a mean of -$30.5 million.
  • Biggest five-year swings in Net Income: plummeted 65.92% in 2023 and later soared 63.42% in 2024.
  • BioXcel Therapeutics' Net Income stood at -$53.5 million in 2022, then soared by 60.74% to -$21.0 million in 2023, then soared by 31.39% to -$14.4 million in 2024, then rose by 3.57% to -$13.9 million in 2025.
  • The last three reported values for Net Income were -$13.9 million (Q4 2025), -$18.4 million (Q3 2025), and -$19.5 million (Q2 2025) per Business Quant data.